

| Project | Intended use for Impact statement | Impact statement: | Headline (<20 words, < 30s if read aloud): |
|----------------------|-----------------------------------|---|--|
| InhibitecAnticuerpos | Written | <p>About one third of patients with psoriatic arthritis (PA) do not respond adequately to the existing therapies. We have identified BMP and activin membrane-bound inhibitor (BAMBI) as a new key player in disease development and produced an inhibitory mAb. Treatment with this mAb has therapeutic effects in preclinical murine models of PA by inhibiting the generation of pro-inflammatory CD4 lymphocytes and by increasing the differentiation and function of protective regulatory T cells.</p> | <p>Treatment with anti-BAMBI monoclonal antibodies has therapeutic effects in preclinical models of psoriatic arthritis.</p> |